BRCA2 GENE MUTATION
Clinical trials for BRCA2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRCA2 GENE MUTATION trials appear
Sign up with your email to follow new studies for BRCA2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough prostate cancer in understudied groups
Disease control TerminatedThis study tested a combination of two drugs, niraparib and abiraterone (plus prednisone), for Hispanic/Latino and Black patients with a specific type of advanced prostate cancer that has spread and has certain gene changes. The goal was to see if the treatment could lower PSA le…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Immunotherapy drug shows promise for hard-to-treat cancers with genetic flaws
Disease control OngoingThis study tests the drug pembrolizumab in people with advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. About 21 adults with metastatic or recurrent cancer took part. Pembrolizu…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for tough cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called talazoparib in 150 people with advanced cancers that have not responded to standard treatments. The drug works by blocking an enzyme that helps cancer cells repair themselves, which may cause them to die. The study focuses on patients whose tumors h…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: BRCA2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 12, 2026 12:10 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused TerminatedThis study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC